



Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies

Guest Editors:

Dr. Patrizia Bonelli

Molecular Biology and Viral
Oncology Unit, Istituto Nazionale
Tumori IRCCS Fondazione G.
Pascale, 80131 Napoli, Italy

Dr. Maria Lina Tornesello

Molecular Biology and Viral
Oncology Unit, Istituto Nazionale
Tumori IRCCS Fondazione G.
Pascale, 80131 Napoli, Italy

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editors

The carcinoma of the anal canal is a rare cancer of the anogenital tract, comprising 2–3% of all gastrointestinal malignancies, with approximately 50,000 new cases and 19,000 deaths in 2020 worldwide. Anal squamous cell carcinoma (ASCC) is the most common histological type and its development is mainly associated with high risk human papillomavirus (HPV) infection and other risk factors including cigarette smoking, HIV infection, genital warts, and lifetime number of sexual partners. The biological characterization of anal cancer has only recently been investigated.

This Special Issue will focus on the state of the art of the molecular characterization of anal cancer, with particular reference to the use of innovative biomarkers for the diagnosis, disease progression, and development of new therapeutic strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)